provides

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

February 24, 2026 16:30 ET  | Source: Cardiff Oncology, Inc. Reported positive update from Phase 2 CRDF-004 trial in first-line…

2 months ago

Inotiv Provides Notice Regarding Cybersecurity Incident

February 13, 2026 16:30 ET  | Source: Inotiv, Inc. WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc.…

3 months ago

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public…

3 months ago

Phaos Technology Holdings (Cayman) Limited Provides Response to Unusual Market Action

SINGAPORE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phaos Technology Holdings (Cayman) Limited, (NYSE American: POAS), (“the Company”), an advanced microscopy…

3 months ago

New Study Reveals Organic NatureKnit Provides Greater Prebiotic Benefits Than Purified Fibers

MOMENCE, Ill., Jan. 21, 2026 /PRNewswire/ -- New research published in Frontiers in Nutrition has revealed the significant impact of Organic…

3 months ago

Valneva Provides Update on Chikungunya Vaccine IXCHIQ

Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and…

3 months ago

InspireSemi Provides Administrative Updates

VANCOUVER, British Columbia and AUSTIN, Texas, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Inspire Semiconductor Holdings Inc. (“InspireSemi” or the “Company”)…

4 months ago

Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa net sales recorded by Orion has potential to exceed EUR 1 billion in the future

January 14, 2026 01:30 ET  | Source: Orion Oyj ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 14 JANUARY 2026 at…

4 months ago

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 11, 2026 13:00 ET  | Source: Krystal Biotech, Inc. Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to…

4 months ago

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued…

4 months ago